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Abstract
Adeno-associated viruses (AAVs) are promising viral vectors for therapeutic gene delivery, and the 
approval of an AAV1 vector for the treatment of lipoprotein lipase deficiency has heralded a new 
and exciting era for this system. However, preclinical and clinical studies show that neutralization 
from pre-existing antibodies is detrimental for medical application and this hurdle must be 
overcome before full clinical realization can be achieved. Thus the binding sites for capsid 
antibodies must be identified and eliminated through capsid engineering. Towards this goal and to 
recapitulate patient polyclonal responses, a panel of eight new mouse monoclonal antibodies 
(MAbs) has been generated against AAV8 and AAV9 capsids, two vectors in development for 
therapeutic application. Native (capsid) dot blot assays confirmed the specificity of these 
antibodies for their parental serotypes, with the exception of one MAb, HL2372, selected to cross-
react against both capsids. Furthermore, in vitro assays showed that these MAbs are capable of 
neutralizing virus infection. These MAbs will be utilized for structural mapping of antigenic 
footprints on their respective capsids to inform development of the next generation of rAAV 
vectors capable of evading antibody neutralization while retaining parental tropism.
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1. Introduction
Major advances have occurred in the development of Adeno-associated viruses (AAVs) as 
gene delivery vectors over the last two decades, including improvements in large scale 
vector production to support clinical trials (Chahal et al. 2014; Martin et al. 2013; Mietzsch 
et al. 2014). Significantly, recent successes in clinical trials worldwide have resulted in the 
approval of the use of the first AAV gene therapy product in Europe for the treatment of 
lipoprotein lipase deficiency (Pollack 2012), and numerous clinical trials are in progress for 
many other disease targets (Bainbridge et al. 2008; Brantly et al. 2009; Daniel Gaudet 2012; 
Ginn et al. 2013; Maguire et al. 2009; Maguire et al. 2008; Mendell et al. 2009; Smith et al. 
2013; Wierzbicki et al. 2013). However, AAV elicits both a cellular and humoral immune 
response which must be overcome for improved vector efficacy. In the general population, 
~40–70% of individuals have been exposed to AAVs (Blacklow et al. 1968; Boutin et al. 
2010; Calcedo et al. 2011; Calcedo et al. 2009; Liu et al. 2013), and a significant number of 
potential patients already harbor pre-existing antibodies to AAVs (Ferreira et al. 2014; 
Halbert et al. 2006; Li et al. 2012; van der Marel et al. 2011). These pre-existing antibodies 
have been shown, even at low levels, to prevent successful gene delivery (Hurlbut et al. 
2010; Manno et al. 2006; Scallan et al. 2006; Wang et al. 2011). In addition, the antibody 
response is likely to interfere with any re-administration of an AAV vector in the event that 
therapeutic levels are not maintained for the lifetime of the patient.
To understand AAV-antibody interactions and identify potential epitopes, the first step is to 
produce and have at hand a panel of anti-AAV antibodies. Here, we generated a panel of 
anti-AAV8 and anti-AAV9 mouse monoclonal antibodies (MAbs) using the hybridoma 
method to aid characterization of their capsid-antibody interactions. AAV8 is known for its 
enhanced hepatic cell transduction (Sands 2011) and has been used in numerous preclinical 
and clinical trials to target the liver (Bell et al. 2011; Nathwani et al. 2007; Nathwani et al. 
2006; Nathwani et al. 2011). AAV9 has been reported to cross the blood-brain barrier 
(Bevan et al. 2011; Federici et al. 2012; Gray et al. 2011; Schuster et al. 2014; Zhang et al. 
2011), and has become the vector of choice for treating genetic disease involving the central 
nervous system (CNS) (Cearley et al. 2007; Fu et al. 2011; Spampanato et al. 2011; Xue et 
al. 2010). However, despite the progress in AAV vector development, detailed antigenic 
footprint information is lacking for both AAV8 and AAV9. Until now, there has only been 
one MAb developed against AAV8 and AAV9, namely ADK8 and ADK9, respectively, and 
one cross-reactive MAb, ADK8/9 (Sonntag et al. 2011). The binding site of ADK8 on the 
AAV8 capsid surface has been identified, through cryo-electron microscopy (cryo-EM) 
reconstruction methods and confirmed by mutagenesis, to be located on the top of the 
protrusions surrounding the icosahedral 3-fold axes of the capsid (Gurda et al. 2012). 
However, the epitope for ADK9 on the AAV9 capsid surface remains unknown. The only 
available AAV9 antigenic information based on an in vivo library screening showed that 
residues 453–457, which are also located in the region of 3-fold protrusion, are important for 
antigenicity (Adachi et al. 2014). Since the antibody response in humans is polyclonal, the 
antigenic information from one monoclonal anti-AAV antibody is not sufficient to mimic 
patient responses. Therefore, in an effort to better understand the region(s) of the AAV8 and 
AAV9 capsids that are immunogenic/immunodominant, we have generated a panel of new 
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antibodies to AAV8 and AAV9 capsids in mice using the hybridoma method. These 
antibodies will facilitate further studies, through molecular and structural biology, that will 
provide a better understanding of the antigenic regions of their respective capsids. This 
information can then be utilized to develop AAV8 and AAV9 variants, through rational 
sitedirected mutagenesis or structure guided directed evolution, with the ability to evade 
antibody neutralization while retaining parental tropism.
2. Materials and Method
2.1. Expression and purification of AAV8 and AAV9 capsids
Recombinant AAV8 and AAV9 virus-like particles (VLPs) were expressed using the Bac-to- 
Bac baculovirus-Sf9 insect cell expression system (Gibco/ Invitrogen,Carlsbad, CA) and 
purified using a 20% sucrose cushion followed by sucrose gradient (5 to 40% [wt/ vol]) as 
previously reported (Lane et al. 2005; Mitchell et al. 2009). Purified AAV8 and AAV9 VLPs 
were concentrated to 1–3 mg/ml and buffer exchanged into 1X PBS, pH 7.4. The 
concentration of the samples was estimated by optical density measurements (using OD280 
and E = 1.7 for calculation in mg/ml), as well as SDS-PAGE gel electrophoresis with BSA 
concentration standards. Prior to use, the purity and integrity of the VLPs were also 
monitored by SDS-PAGE and negative stain EM, respectively (data not shown).
2.2. Generation of AAV capsid specific monoclonal antibodies
The anti-AAV8 and anti-AAV9 hybridoma clones were generated in collaboration with the 
Interdisciplinary Center for Biotechnology Research (ICBR) Hybridoma Core Lab, 
University of Florida. Six-week-old female BALB/CByj mice were immunized three times 
with subcutaneous injections of 5, 10, 25, 50 or 75 μg of AAV capsids at 21-day intervals 
and one intraperitoneal injection on day 120 as the last boost. The first three subcutaneous 
injections were accompanied by a Sigma Adjuvant System (Sigma-Aldrich, St. Louis, MO), 
which contain 0.5 mg monophosphoryl lipid A, 0.5 mg synthetic trehalose 
dicorynomycolate in 44 μl squalene oil, 0.2% TWEEN 80 and water. Test bleeds from 
immunized animals were obtained 10–14 days after every booster injection, following 
animal care protocols. The collected sera were tested for high specific antibody response 
using ELISA and Dot Blot (against intact capsid) assays as described below. Four days after 
the final boost injection, the splenocytes of immunized mice were fused with mouse 
myeloma Sp2/0 cells using 50% PEG 1500 (polyethylene glycol) as the fusing agent. The 
fused hybrids were cultured in HAT (hypoxanthine-aminopterin-thymidine) (Sigma-Aldrich, 
St. Louis, MO) supplemented Dulbeccos Modified Eagles Medium (DMEM) to eradicate 
the unfused myeloma cells. To obtain the positive hybridoma clones, with highest specific 
anti-AAV capsid antibody response, the supernatants from the resulting hybridoma cells 
were collected and screened by total of 5 rounds of ELISA assays, as described below. Use 
of Animals in the UF Hybridoma Core Lab at University of Florida is under the guidelines 
of the Institutional Animal Care and Use Committee.
2.3. Screening of mice serum or hybridoma supernatants using VLP ELISA
The supernatants of hybridomas were screened in the Hybridoma Core Lab, ICBR, 
University of Florida, using AAV8 and AAV9 virus-like particles (VLPs) ELISA assays. 
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Briefly, Nunc Maxisorp 96 well plates (Thermo Scientific, Rochester, NY) were coated with 
AAV VLPs at 4°C O/N prior to each ELISA assay. The plates were then blocked with 1% 
BSA in PBS at RT for 1 h, and then washed with washing buffer (1×PBS with 0.5% Tween 
20). The immunized mouse serum or the hybridoma supernatants were applied to the plate 
and incubated at RT for 1 h. After washes, the secondary antibody, a rabbit anti-mouse IgG 
whole molecule AP (alkaline phosphatase), goat anti-mouse IgG gamma chain specific AP, 
or goat anti-mouse IgM mu chain specific AP (Sigma-Aldrich, St. Louis, MO) were added at 
1:1000, 1:4000, and 1:4000 dilution in PBS with 1% BSA, respectively, for 1 h at RT. 
Finally after several washes, the substrates, p- Nitrophenyl Phosphate Disodium (Sigma), 
was applied to the plate and incubated for 1 h, then optical density readings were taken at 
405 nm using a Molecular Devices SpectraMax 384 Plus (Sunnyvale, CA).
2.4. Anti-AAV VLP dot blot analysis
AAV VLPs were allowed to adsorb onto supported nitrocellulose membranes (Bio-Rad, 
Hercules, CA) in the dot blot manifold (Schleicher and Schuell, Dassel, Germany). Excess 
fluid was drawn through the membrane by vacuum filtration. The membrane was removed 
from the manifold and blocked with 10% milk in PBS, pH 7.4 for 1 h. Primary antibody in 
the form of anti-AAV mouse serum, hybridoma supernatant, or the purified MAbs, in 
different dilutions depending on the sample being tested, was applied to the membrane in 
PBS with 5% milk and incubated for 1 h. Following this, the membrane was washed with 
PBS and horse radish peroxidase (HRP)-linked secondary antibody was applied at a dilution 
of 1:5000 in PBS and incubated for 1 h. The membrane was washed with PBS and then 
Super Signal West Pico Chemiluminescent Substrate (ThermoFisher, Waltham, WA) was 
applied to the membrane and the signal detected on X-ray film. The B1 antibody, which 
binds to the C terminus of the viral capsid proteins in all the AAV serotypes except for 
AAV4 (Wistuba et al. 1995), was used as a control to confirm the presence of AAV capsid 
proteins using denatured capsids (boiled and blotted). ADK8 and ADK9 (Sonntag et al. 
2011) were used as positive controls for AAV8 and AAV9, respectively, to detect in intact 
(non-boiled) capsids.
2.5. Determination of the isotypes for the anti-AAV MAbs
The isotypes of the newly generated anti-AAV antibodies were determined in the ICBR 
Hybridoma Core Lab, University of Florida, using the IsoStrip Mouse Monoclonal Antibody 
Isotyping Kit (Satnta Cruz Biotechnology, Santa Cruz, CA). The supernatant of the 
hybridoma cell cultures were diluted 1:10 to 1:100 in PBS depending on the concentration 
of antibodies in the supernatant. The diluted samples were loaded onto the development tube 
provided in the kit and incubated for 30 s. One isotyping strip was placed in each 
development tube and incubated for 5–10 min until appearance of the blue bands for which 
their positions indicate the isotype (IgG1, IgG2a, IgG2b, IgG3, IgM or IgA) and the light 
chain type (kappa or lambda) of the MAb.
2.6. Neutralization assay
The neutralization abilities of the newly generated anti-AAV8 and anti-AAV9 antibodies 
were assayed in HeLa cells (Veron et al. 2012). Briefly, luciferase gene packaged 
recombinant rAAV8-Luc or rAAV9-Luc vectors were mixed with different hybridoma 
Tseng et al. Page 4
J Virol Methods. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
supernatants in a volume ratio 1:1, and then used to infect HeLa cells at a 10,000 MOI 
(multiplicity of infection). After 24 hours, the cells were lysed and the expressed luciferase 
activity was assayed for each complex using a luciferase assay (Promega, Madison, WI) as 
described in the manufacturer's protocol. In this assay, ADK4, a MAb that specifically 
recognizes AAV4 (Kuck et al. 2007) was used as a negative control while ADK8 and ADK9, 
known to neutralize infection by AAV8 (Gurda et al. 2012) and AAV9 (Sonntag et al. 2011), 
respectively, were used as positive control.
3.0 Results
3.1. New panel of anti-AAV8 and anti-AAV9 antibodies
Two anti-AAV8 (designated HL2381 and HL2383; HL stands for Hybridoma Lab) and four 
anti-AAV9 (HL2368, HL2370, HL2372, and HL2374) IgG antibodies were generated in 
mice by 3 subcutaneous and 1 intraperitoneal immunization of AAV8 or AAV9 capsids, 
respectively, in 6 week old BLAB/CByj mice (Table 1). The clones were selected from fused 
hybridoma hybrids after capsid ELISA and dot blot screenings. All the 6 antibodies 
generated only bind to intact capsids (Figure 1) not the linear viral proteins when tested in 
Western blot assays (data not shown). The isotypes of these new anti-AAV antibodies were 
identified: the 2 anti-AAV8 antibodies, HL2381 and HL2383, are both IgG3; the 4 anti-
AAV9 antibodies, HL2368, HL2370, HL2372, and HL2374, are IgG3, IgG2a, IgG2a, and 
IgG3, respectively (Table 1).
3.2. The HL MAbs are serotype specific, with the exception of HL2372 that cross-reacts 
with AAV8 and AAV9
To check the cross-reactivity of the MAbs against different AAV serotypes, the anti-AAV8 
and anti-AAV9 antibodies were used as primary antibodies to probe the intact capsids of 
AAV1- AAV9 in a native dot blot assay (Fig. 1). The B1 antibody confirmed the presence of 
AAV capsid proteins, with the exception of AAV4 (Fig.1 A), while ADK8 and ADK9 
confirmed the presence of AAV8 and AAV9 capsids (Fig.1 B and C). Two anti-AAV8 
antibodies, HL2381 and HL2383, were able to recognize AAV8 as predicted, but also cross 
reacted with AAV3B (Fig.1 B), which has also been observed for the ADK8 antibody 
(Sonntag et al. 2011). During the clonal selection, one anti-AAV9 clone, HL2372, exhibited 
binding to both AAV8 and AAV9. This cross-reactivity was confirmed by dot blot assay 
(Fig. 1 C). All other anti-AAV9 antibodies, HL2368, HL2370, and HL2374, bound to AAV9 
only (Fig. 1 C).
3.3. The HL series of anti-AAV8 and anti-AAV9 MAbs are neutralizing
The in vitro neutralization abilities of the anti-AAV8 and anti-AAV9 antibodies were 
assayed in HeLa cells (Fig. 2). The ADK8 and ADK9 MAbs (Sonntag et al. 2011) used as 
positive controls were observed to neutralize infection. However, ADK4, a MAb that 
specifically recognizes AAV4 (Kuck et al. 2007), was used as a negative control and was not 
able to neutralize the infection of rAAV8 (Fig. 2 A) or rAAV9 (Fig. 2 B), with the resulting 
luciferase activities being similar in the virus+ADK4 and virus-only groups (Fig. 2). In the 
virus+ADK8 and virus+ADK9 groups, the luciferase activities were decreased ~20 fold in 
relative light units (RLUs) compared to the virus-only groups (Fig. 2 A and B, respectively). 
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Similar results were observed with virus mixed with HL2368, HL2370, HL2372, HL2374, 
HL2381, and HL2383, suggesting that all the antibodies can neutralize infection in cells, as 
observed with ADK8 (Fig. 2 A) and ADK9 (Fig. 2 B).
4. Discussion
With recent advances in the development of AAVs as gene therapy vectors or for use as 
active (protein expression) and passive (antibody expression) delivery systems for 
vaccination, there is a need for a better understanding of their antigenic reactivity and anti-
body binding site structures. In addition, there is an ever expanding pool of AAV variants 
being developed for specific tissue targeting and improved efficacy. Advancing these studies 
requires the availability of more anti-AAV capsid antibodies as detecting tools as well as for 
elucidating antigenic footprints for engineering host immune recognition escape. The 
developed HL panel of anti-AAV8 and anti-AAV9 hybridoma clones described expands the 
pool of known anti-AAV8 and anti-AAV9 antibodies. These new antibodies showed in vitro 
neutralizing ability at the same level as ADK8 and ADK9, indicative of binding sites that 
enable functions required for infection (Fig. 2). Structural characterization of the binding 
site(s) for these MAbs will aid the design of neutralization escaping vectors to evade the 
polyclonal antibody response that is pre-existing in the human population.
The six new HL MAbs are either IgG2a or IgG3. In a previous study to create anti-AAV2 
MAbs, although both Balb/c and C57B1/6 mice were intramuscularly (i.m) immunized with 
capsids, high titers of IgG2a and IgG3 were induced in the Balb/c mice but only IgG2a 
isotypes were observed in the C57B1/6 mice (Chirmule et al. 2000). Other studies have 
shown that C57B1/6 mice tend to generate IgG2a and IgG2b antibodies when immunized 
with AAVs (Kuck et al. 2007; Sonntag et al. 2011; Zhang et al. 2005). In this study, IgG2a 
and IgG3 antibodies were also generated in Balb/c mice (Table 1), similar to the observation 
by Chirmule et al in Balb/c mice despite different immunization routes: subcutaneous (this 
study) versus i.m (Chirmule et al. 2000). This suggests that AAVs have an IgG isotype 
preference. However, in another study using subcutaneous immunization in Balb/c mice, a 
spectrum of MAb isotypes were selected, including IgG1, IgG2a, IgG2b, IgG3, and IgM 
(Harbison et al. 2012). The only significant difference between this work and that by 
Harbison et al was the administration route of the final boost. Rather than using 
intraperitoneal injections, Harbison et al used intravenous injections. Interestingly, structure 
characterization of the antibodies generated in their study showed the fragment antibody 
binding footprints to be mostly overlapping on the capsid surface and a large number of the 
MAbs were IgM suggesting that further maturation was required or perhaps further clonal 
selection would have narrowed the spectrum of isotypes observed. These observations 
indicate that the relationship between virus and infected host is complex with respect to 
MAb generation, maturation, and isotype switching and requires further investigation. It is 
likely that the genetic backgrounds of animal strains, antigen dose, and routes of antigen 
administrations may cause different IgG subclass profiles to be generated.
The six hybridoma clones reported in this study were generated from mice immunized with 
either AAV8 or AAV9. However, three of the antibodies generated bind to more than one 
AAV serotype: HL2381 and HL2383 bind to both AAV8 and AAV3B, and HL2372 
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generated against AAV9 also binds to AAV8 (Fig. 1). Other known anti-AAV monoclonal 
antibodies shown to be cross-reactive to AAV capsids that were not used for generation 
include ADK1a and ADK1b, isolated from spleen cells of mice immunized with AAV1 yet 
bind to AAV6 capsids (Kuck et al. 2007). This is likely due to the high sequence identity 
(~99%) between the AAV1 and AAV6 capsid viral proteins, where only six amino acids 
differ between them (Ng et al. 2010), and the fact that the footprint mapped for ADK1a and 
ADK1b do not contain these differing residues. Similarly AAV1/AAV6 cross reactivity has 
also been observed for the 4E4 and 5H7 anti-AAV1 antibodies generated against AAV1 
(Harbison et al. 2012). Unlike AAV1 and AAV6, the sequence identity between AAV3B and 
AAV8 is ~83% and between AAV8 and AAV9 is ~82%, and the overall structural overlay 
identity is slightly higher at ~86% between AAV3 and AAV8, and ~88% between AAV8 and 
AAV9. However, AAV8 and AAV9 both also show ~88% structural identity to AAV1, 
AAV2, and AAV6, and these new antibodies did not exhibit cross reactivity to these three 
serotypes. These observations suggest common surface properties between the serotypes for 
which cross reactivity is observed. In addition, it is noteworthy that ADK8, generated from a 
different mice strain, with different immunization protocol (Sonntag et al. 2011), also binds 
to AAV3B (Fig. 1B). All three antibodies, HL2381, HL2383, and ADK8, only bind to intact 
AAV capsids, suggesting that there must be common antigenic structural characteristics 
shared between the AAV3B and AAV8 capsid surfaces. These observations generate a need 
to better understand the antigenic properties of these AAV serotypes to enable antibody 
escape vectors because of the polyclonal anti-AAV response observed in the human 
population.
In summary, we have expanded the number of anti-AAV8 and anti-AAV9 antibodies 
available to the AAV community which can be used as tools to study the antigenic properties 
of wild type AAV8 and AAV9. They will also serve as reagents for characterizing variants 
being developed for improved therapeutic efficacy.
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Highlights
• A panel of mouse monoclonal antibodies were generated against AAV8 
and AAV9
• The new MAbs recognize conformational epitopes
• In vitro virus neutralization by new antibodies suggests recognition of 
functional regions
• The new MAbs provide tools for characterization of AAV8 and AAV9 
variants being developed for improved therapeutic efficacy
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Figure 1. 
Cross reactivity of HL antibodies. (A) Position map of AAV serotypes and B1 antibody 
(Wobus et al. 2000) reactivity of AAV1-AAV9, the representative members of the AAV 
antigenic clades and clonal isolates (Gao et al. 2004). (B) The cross-reactivity the anti-AAV8 
antibodies against different AAV serotypes: ADK8 (Sonntag et al. 2011) as a positive 
control, and the new anti-AAV8 HL antibodies, HL2381 and HL2383. (C) The cross-
reactivity of the anti-AAV9 antibodies against different AAV serotypes: ADK9 (Sonntag et 
al. 2011) as a positive control, and the anti-AAV9 HL antibodies, HL2368, HL2370, 
HL2372, and HL2374.
Tseng et al. Page 12
J Virol Methods. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
In vitro neutralization by HL antibodies. (A and B) The transduction efficiency of rAAV8 
and rAAV9, respectively, as measured by luciferase activity, in the absence/presence of the 
HL antibodies. The ADK4 antibody was used as a negative control, while ADK8 and ADK9 
were used as positive controls, respectively.
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Table 1
The anti-AAV8 and anti-AAV9 HL series of antibodies
Antibody ID Against serotype Isotype
HL2368 AAV9 IgG3
HL2370 AAV9 IgG2a
HL2372 AAV9 IgG2a
HL2374 AAV9 IgG3
HL2381 AAV8 IgG3
HL2383 AAV8 IgG3
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